News

LifeNet Health’s Rapid Growth Continues with Acquisition of State-of-the-Art Virginia Beach Research Laboratory

A company that is a global leader in regenerative medicine has acquired a cutting-edge research laboratory in Virginia Beach. LifeNet Health will use the laboratory as a center of excellence for groundbreaking liver disease research and sports medicine applications. The dual function will provide better health solutions for a growing number of patients.

Situated near Town Center, the approximately 5,700-square-foot space, previously managed by the City of Virginia Beach, has long been intended as a home for life sciences research. In partnership with the City of Virginia Beach, LifeNet Health secured the state-of-the-art facility, adding to the company’s rapidly expanding regional impact.

LifeNet Health has spent the past four-plus decades expanding transplantation services for residents of Virginia, forging new advancements in allograft implants, and researching cellular therapies for breakthrough discoveries.

 This latest acquisition underscores the company’s dedication to using life sciences research to revolutionize patient outcomes, with the aim of transforming the prognosis for the more than 100 million people worldwide who currently suffer from an inflammatory liver condition called nonalcoholic steatohepatitis (NASH) or assist those who deal with chronic knee and joint degeneration.

In partnership with the City of Virginia Beach, LifeNet Health secured the state-of-the-art facility, adding to the company’s rapidly expanding regional impact. The acquisition is a significant milestone in an extended period of double-digit growth for LifeNet Health, which currently employs about 1,000 employees in Virginia Beach and close to 1,500 globally. Since 2023, the company has hired more than 500 new employees across various locations, a 37% increase overall.

“I am immensely proud of LifeNet Health’s progress and the transformative potential this new laboratory represents,” said LifeNet Health President and CEO Rony Thomas. “Our home is Hampton Roads, and we take great pride in delivering for not only patients but for our neighbors as well. This facility will be a cornerstone of our life sciences research programs, significantly enhancing our ability to address critical health challenges. By expanding our presence in Virginia Beach, we are not only advancing medical science but also contributing to the economic vitality of the region.”

The acquisition of this innovative facility underscores LifeNet Health’s commitment to driving innovation and economic growth in the region. 

“We are thrilled that one of the world’s most recognizable companies in the medical science space is expanding to Virginia Beach,” said Amanda Jarratt, deputy city manager for the City of Virginia Beach. “Not only will this move provide high-value jobs, but it will also contribute to Virginia Beach’s economic growth, further positioning the city as a life sciences hub. We congratulate the LifeNet Health team on the expansion in Virginia Beach and look forward to a positive, successful partnership.”

LifeNet Health’s acquisition of the facility brings years of potential promise to fruition, positioning the region at the forefront of innovation for years.

“We are excited to widen our footprint and generate new jobs in Virginia Beach, especially when many organizations are downsizing,” said John Herre, MD, chair of the LifeNet Health Board of Directors. “Virginia Beach has been a consistent and nurturing partner for LifeNet Health for over 40 years, and we are eager to continue that relationship and play a pivotal role in revitalizing its downtown, solidifying its status as a life sciences hub.”

Read more here.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation